Milestone Pharmaceuticals
Milestone Pharmaceuticals
MIST
NASDAQ
1.88
USD
3.87%
About
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients.
The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 110.9K |
| Three Month Average Volume | 2.2M |
| High Low | |
| Fifty-Two Week High | 3.52 USD |
| Fifty-Two Week Low | 1.12 USD |
| Fifty-Two Week High Date | 05 Dec 2023 |
| Fifty-Two Week Low Date | 02 Jul 2024 |
| Price and Volume | |
| Current Price | 1.42 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.31% |
| Thirteen Week Relative Price Change | -11.55% |
| Twenty-Six Week Relative Price Change | -19.79% |
| Fifty-Two Week Relative Price Change | -57.72% |
| Year-to-Date Relative Price Change | -28.20% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -5.33% |
| Twenty-Six Week Price Change | -11.80% |
| Five Day Price Change | -3.40% |
| Fifty-Two Week Price Change | -47.01% |
| Year-to-Date Price Change | -14.97% |
| Month-to-Date Price Change | -1.39% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.50088 USD |
| Book Value Per Share (Most Recent Quarter) | 0.60031 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.50088 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.60031 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.97243 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.02328 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.38945 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.01497 USD |
| Normalized (Last Fiscal Year) | -1.38945 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.38945 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.01497 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.38945 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.01497 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.97123 USD |
| Cash Per Share (Most Recent Quarter) | 1.56286 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.38731 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.95486 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.73123 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,118 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -5,968.50% |
| Pretax Margin (5 Year) | -1,267.60% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -6,109.80% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -1,297.16% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -5,968.50% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -1,267.25% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -32.34% |
| Tangible Book Value (5 Year) | -27.47% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 86.23% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 62.13% |
| EPS Change (Trailing Twelve Months) | 26.08% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -31,722,000 |
| Net Debt (Last Fiscal Year) | -16,231,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 76 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 297 |
| Long Term Debt to Equity (Most Recent Quarter) | 161 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 10 |
| Current Ratio (Most Recent Quarter) | 19 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -46,536,000 |
| Free Cash Flow (Trailing Twelve Months) | -36,992,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 297 |
| Total Debt to Equity (Most Recent Quarter) | 161 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -79.73% |
| Return on Assets (Trailing Twelve Months) | -51.98% |
| Return on Assets (5 Year) | -48.44% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -143.61% |
| Return on Equity (Trailing Twelve Months) | -133.75% |
| Return on Equity (5 Year) | -63.70% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -87.55% |
| Return on Investment (Trailing Twelve Months) | -55.36% |
| Return on Investment (5 Year) | -51.56% |